More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

S&P DJI Announces March 2019 Quarterly Rebalance

Mar 7, 2019 at 9:43 PM EST · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Mar 7, 2019 at 9:43 PM EST · 6 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2019-quarterly-rebalance-44

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

  • Paradigms orphan Phase 2/3 clinical program progressesFeb 13, 2019
  • Paradigms supplementary Phase 2B dataDec 19, 2018
  • Presentation of Phase 2 clinical trial resultsDec 17, 2018
  • PAR reports successful Phase 2 clinical trialDec 17, 2018
  • Paradigm reports consistent OA pain reductionDec 6, 2018

Later from Paradigm Biopharmaceuticals

  • Paradigm (PAR) Updated Investor PresentationMar 12, 2019
  • Paradigms secondary endpoints successfully metApr 14, 2019
  • Paradigm launches a$77.9M capital raiseApr 14, 2019
  • Paradigm updated corporate presentationApr 14, 2019
  • Paradigm Confirms Capital Raise CommitmentsApr 16, 2019
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer